Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
United States
Tel: 650-421-8100
Website: http://www.codexis.com/
About Codexis, Inc.
Codexis is a leading enzyme engineering company leveraging our proprietary CodeEvolver® technology platform to discover and develop novel, high performance enzymes for three healthcare industry pillars: pharmaceutical manufacturing, life sciences, and biotherapeutic discovery & development. The enzymes we produce aim to solve real-world challenges associated with small molecule pharmaceuticals manufacturing, nucleic acid synthesis and genomic sequencing, and - as biotherapeutic candidates - they have the potential to treat challenging diseases. To meet this goal, we look for individuals who are driven, eager to grow and ready to embrace meaningful challenges. We empower employees to be authentic, ambitious, agile and have the courage to take action where they can make a positive impact. Whether you are driven by science, or a different area of expertise, we need you to help us create a brighter future.
Are you ready to join our mission to fight rare diseases? Are you interested in enhancing protein optimization and production? Do you have a passion to help people have better quality of life? Come be part of the Codexis, Inc. team where every day we get to unlock the power of proteins®!
Codexis uses our world-leading CodeEvolver® protein engineering platform to discover novel therapies for the treatment of genetic disorders and other debilitating disease and to develop custom enzymes for a wide range of applications. We engineer proteins with high efficacy and safety with the goal of delivering the therapeutic to patients as an enzyme replacement, mRNA, or gene therapy.
But we can't do it without YOU!
We are rapidly growing, and we are presently seeking to expand our pipeline and diversify applications of our technology platform. We have a number of opportunities for passionate scientists that want to do something
76 articles about Codexis, Inc.
-
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder
6/10/2021
Codexis, Inc. announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited for the research and development of an additional gene therapy for a lysosomal storage disorder bringing the total number of programs under the agreement to four.
-
Codexis to Participate in Upcoming Virtual Healthcare Conferences
5/25/2021
Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences.
-
Codexis to Participate in Upcoming Virtual Healthcare Conferences - May 17, 2021
5/17/2021
Codexis, Inc., a leading enzyme engineering company, announced that management will participate in three upcoming virtual investment conferences.
-
Codexis Reports First Quarter 2021 Financial Results
5/6/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the first quarter ended March 31, 2021 and provided a business update.
-
Codexis to Report First Quarter 2021 Financial Results on May 6
4/22/2021
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2021 on Thursday, May 6, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.
-
Codexis Reports Fourth Quarter and Fiscal Year 2020 Financial Results
2/25/2021
Strong Product Revenue Momentum in Second Half of 2020 Drives Company’s Seventh Consecutive Year of YOY Revenue Growth
-
Codexis to Present at Upcoming Virtual Healthcare Conferences
2/18/2021
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtual investment conferences.
-
Codexis to Report Fourth Quarter and Full Year 2020 Results on February 25
2/11/2021
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.
-
Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth
2/9/2021
Codexis, Inc., a leading enzyme engineering company, announced it will be expanding its operations into a new 36,000 square foot facility in San Carlos, CA under a ten year lease.
-
Codexis Appoints Dr. Esther Martinborough to its Board of Directors
2/3/2021
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors.
-
Codexis Introduces Improved Enzymes to Further Enhance Tate & Lyle's Stevia and Allulose Production
1/13/2021
Codexis, Inc., a leading protein engineering company and developer of high-performance enzymes, and Tate & Lyle, a leading global provider of food ingredients and solutions, have extended and deepened their relationship to enhance the production of two of Tate & Lyle’s newest sweeteners: DOLCIA PRIMA® Allulose and TASTEVA® M Stevia Sweetener.
-
Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference
1/5/2021
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that John Nicols, the Company’s President and Chief Executive officer, will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021. A replay of the pre-recorded fireside chat will be available beginning Monday, January 11, at 6:00 a.m. ET and will be archived on the Investor
-
Codexis Announces Pricing of Public Offering of Common Stock - Dec 03, 2020
12/3/2020
Codexis, Inc., a leading protein engineering company, announced the pricing of an underwritten public offering of 4,285,715 shares of its common stock at a public offering price of $17.50 per share.
-
Codexis Announces Proposed Public Offering of Common Stock
12/2/2020
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock.
-
Codexis to Participate at Three Virtual Investment Conferences in November 2020
11/9/2020
Codexis, Inc., a leading protein engineering company, announces that management will participate at three upcoming virtual investment conferences
-
Codexis Reports Third Quarter 2020 Financial Results
11/5/2020
Higher sequential sales expected again in the fourth quarter, showing growing momentum as we close 2020